Hofseth BioCare ASA reported total operating revenues of NOK 72.2 million in the fourth quarter (Q4) of 2025. Net operating revenues for the quarter were NOK 71.1 million. For the full year (FY) 2025, total operating revenues amounted to NOK 256.3 million. EBITDA for Q4 2025 was negative NOK 26.5 million, while operational EBITDA stood at negative NOK 19.7 million. The operating result $(EBIT)$ for the quarter was negative NOK 37.4 million. For the full year, EBITDA was negative NOK 72.9 million and operational EBITDA was negative NOK 39.5 million. Cash and cash equivalents at the end of December 2025 totaled NOK 67.1 million, with total liquidity, including available credit facilities, at NOK 77.5 million. During the period, Hofseth BioCare ASA achieved significant business milestones. Human Nutrition B2B revenues increased by a multiple of four year-on-year, driven by strong demand for ProGo, CalGo, and a solid sales start for NT-II. The company expanded regulatory access with ingredient approvals in Australia and South Korea, opening new market opportunities. Pet Nutrition B2B volumes and revenues improved compared to the previous quarter, supported by increased customer engagement and trade-show activity. Consumer & Pet Health profitability improved with higher margins year-on-year despite broadly flat revenues. In research and development, the company achieved key milestones including a peer-reviewed publication of the CalGo bone health study, IRB approval for a clinical NT-II joint health study, and progress in oncology, asthma, and gastrointestinal programs through AecorBio Inc. Hofseth BioCare ASA also raised NOK 158 million in a private placement and sold a stake in AecorBio Inc. for USD 5 million to support continued investment in growth, research and development, and capacity expansion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hofseth BioCare ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001164559-en) on February 13, 2026, and is solely responsible for the information contained therein.